Loading clinical trials...

Copeptin and Thirst: Possible Predictive Markers of Effectiveness of Bariatric Surgery? | Clinical Trials | Clareo Health

RECRUITING

Copeptin and Thirst: Possible Predictive Markers of Effectiveness of Bariatric Surgery?

NCT06806787•IRCCS Azienda Ospedaliero-Universitaria di Bologna

View on ClinicalTrials.gov

Summary

Prospective, non-pharmacological, spontaneous, single-center, interventional study.

Detailed Description

COPTBAR is a prospective, nonpharmacological spontaneous single-center interventional study. Laboratory tests and imaging study (complete abdomen ultrasonography) for monitoring patients will be conducted in accordance with normal clinical practice. In addition, periodic copeptin assay will be performed. Each patient, within the study protocol, will be evaluated for 12 months; thereafter, each patient will fall under the follow-up visits provided by normal clinical practice and by Corporate Diagnostic Therapeutic Pathway (PDTA).

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•BMI ≥ 40 in the absence of comorbidities; BMI ≥ 35 associated with at least one comorbidity
•Age ≥ 18 and less than or equal to 65 years
•Written informed consent obtained

Exclusion Criteria

•Contraindications to bariatric surgery:
•severe psychiatric illness in the decompensation phase;
•drug or alcohol abuse;
•patient unwilling to follow periodic checkups and a dietary regimen pregnancy or lactation.
•Factors that could alter ADH/copeptin:
•Obesity induced by other endocrinopathies or medications;
•Diabetes mellitus of any type;
•Malignant neoplasms or ongoing acute disease;
•Organ failure or chronic CNS and kidney disease;
•Hydro-electrolyte alterations;
+1 more criteria

Locations (1)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Bologna, Italy

Key Dates

Start Date

September 13, 2023

Primary Completion Date

March 13, 2026

Completion Date

March 14, 2026

Last Updated

February 4, 2025

Enrollment

ESTIMATED participants

Conditions

Obesity

Contacts

Uberto Pagotto, MD

CONTACT

+390512144190 uberto.pagotto@unibo.it

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

RECRUITING

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Copeptin and Thirst: Possible Predictive Markers of Effectiveness of Bariatric Surgery?

Inclusion Criteria

Exclusion Criteria

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Protein Supplementation Intervention on Body Weight

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss